A Philadelphia-area pharmaceutical company developing innovative treatments for bone disorders has raised fresh capital, likely working toward the commercialization of an osteoporosis treatment.
Zelos Therapeutics has raised $2.8 million, according to a recent filing with the Securities and Exchange Commission. President and CEO Brian MacDonald was not available to comment on the fund-raise.
The company’s leading drug candidate is ZT-031, for the prevention of vertebral fractures in postmenopausal women. In July 2008, the company received the go-ahead from the U.S. Food and Drug Association to proceed with a 24-month Phase 3 clinical trial for the drug. It is also developing a nasal spray osteoporosis treatment to compete with Eli Lilly’s Forteo.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Zelos is a spin-out of the National Research Council Canada and was established in 2000. The company has raised more than $70 million from investors including Alta Partners, Prospect Ventures, VenGrowth Capital, Seaflower Ventures and Genesys Capital.